Serina Therapeutics, Inc.(SER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SER Serina Therapeutics, Inc.

Post-Mkt 05-14 17:27:36 EDT

1.72

+0.16

+10.26%

盘后1.74

+0.02+1.16%

17:04 EDT

High1.81	Low1.55	Vol170.85K
Open1.55	D1 Closing1.56	Amplitude16.67%
Mkt Cap25.63M	Tradable Cap9.14M	Total Shares14.90M
T/O283.72K	T/O Rate3.22%	Tradable Shares5.31M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SER","market":"US","secType":"STK","nameCN":"Serina Therapeutics, Inc.","latestPrice":1.72,"timestamp":1778788800000,"preClose":1.56,"halted":0,"volume":170848,"hourTrading":{"tag":"盘后","latestPrice":1.74,"preClose":1.72,"latestTime":"17:04 EDT","volume":6,"amount":10.379999999999999,"timestamp":1778792691890,"change":0.02,"changeRate":0.011628,"amplitude":0.011628},"delay":0,"changeRate":0.1025641025641025,"floatShares":5311700,"shares":14898599,"eps":-1.90736,"marketStatus":"Post-Mkt","change":0.16,"latestTime":"05-14 17:27:36 EDT","open":1.55,"high":1.81,"low":1.55,"amount":283722.3873472,"amplitude":0.166667,"askPrice":1.88,"askSize":100,"bidPrice":1.4,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.90736,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1778803200000},"marketStatusCode":4,"adr":0,"exchange":"AMEX","adjPreClose":1.56,"preHourTrading":{"tag":"盘前","latestPrice":1.5598,"preClose":1.56,"latestTime":"09:19 EDT","volume":202,"amount":308.3699882,"timestamp":1778764763808,"change":-0.0002,"changeRate":-0.000128,"amplitude":0.051282},"postHourTrading":{"tag":"盘后","latestPrice":1.74,"preClose":1.72,"latestTime":"17:04 EDT","volume":6,"amount":10.379999999999999,"timestamp":1778792691890,"change":0.02,"changeRate":0.011628,"amplitude":0.011628},"volumeRatio":2.409248},"requestUrl":"/m/hq/s/SER/wiki","defaultTab":"wiki","newsList":[{"id":"2635723544","title":"Serina Therapeutics Q1 FY26 net loss widens to $6.9 million from Q1 FY25","url":"https://stock-news.laohu8.com/highlight/detail?id=2635723544","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635723544?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789108,"startTime":"0","endTime":"0","summary":"Serina Therapeutics posted a net loss of USD 6.9 million for quarter ended March 31, 2026, widening from USD 4.82 million year earlier.Operating loss widened to USD 6.28 million as operating expenses rose to USD 6.28 million, led by research and development costs of USD 3.2 million.Other expense swung to USD 611,000 from other income of USD 1.04 million, driven by a non-cash loss tied to amendment of convertible notes in connection with March 2026 PIPE.Cash and cash equivalents totaled USD 24.5 million at March 31, 2026; net cash used in operating activities was USD 4.57 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL6Vhn6L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632305519","title":"Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2632305519","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632305519?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:00","pubTimestamp":1777892400,"startTime":"0","endTime":"0","summary":"Data highlight both SER-603’s rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomar","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3286554/0/en/Seres-Therapeutics-Presents-Preclinical-Data-at-Digestive-Disease-Week-DDW-2026-Supporting-SER-603-a-Next-Generation-Cultivated-Live-Biotherapeutic-Candidate-for-Inflammatory-Bowel.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCRB","SER","BK4139","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629709257","title":"SER Industries Gets BSE's Approval for Name Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2629709257","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629709257?lang=en_us&edition=fundamental","pubTime":"2026-04-22 14:28","pubTimestamp":1776839328,"startTime":"0","endTime":"0","summary":"Logistic service provider SER Industries  has received approval from the BSE stock exchange to \"Desi Farms India\" with effect from April 21, according to a same-day filing to the BSE.The company's equity shares will be traded under scrip ID \"DESIFARMS\" with effect from April 27.The company's shares were up 2% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BSE","SER","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629063480","title":"Serina Therapeutics names Srini Tenjarla chief technology officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2629063480","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629063480?lang=en_us&edition=fundamental","pubTime":"2026-04-22 05:13","pubTimestamp":1776805990,"startTime":"0","endTime":"0","summary":"Serina Therapeutics named Srini Tenjarla chief technology officer on April 20, 2026.Tenjarla previously served as senior vice president of CMC and formulation at Serina  since July 2024.Company raised base salary for CEO Steve Ledger on April 15, 2026, tied to strategic goals under his employment agreement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL7CBsWR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628174260","title":"Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2628174260","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628174260?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:00","pubTimestamp":1776682800,"startTime":"0","endTime":"0","summary":"Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/20/3276845/0/en/Seres-Therapeutics-Showcases-SER-155-Data-and-Live-Biotherapeutic-Insights-at-ESCMID-Global-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","BK4006","IBD","MCRB","AMR","SER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625934477","title":"Serina Therapeutics presents POZ-based lipid nanoparticle data at LNP formulation summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2625934477","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625934477?lang=en_us&edition=fundamental","pubTime":"2026-04-07 18:46","pubTimestamp":1775558775,"startTime":"0","endTime":"0","summary":"Serina to present at 5th LNP Formulation & Process Development Summit in Boston, Massachusetts.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL636Zt1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014039.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","BK4139","NDAQ","SG9999014013.SGD","BK4585","LU2095319765.USD","SER","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","BK4588","IE00BN0W2V16.EUR","BK4112","LU2210150020.SGD","SG9999014021.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624805646","title":"BRIEF-Serina Therapeutics Announces NYSE American Acceptance Of Continued Listing Compliance Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2624805646","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624805646?lang=en_us&edition=fundamental","pubTime":"2026-04-03 05:34","pubTimestamp":1775165692,"startTime":"0","endTime":"0","summary":"BRIEF-Serina Therapeutics Announces NYSE American Acceptance Of Continued Listing Compliance PlanApril 2 (Reuters) - Serina Therapeutics Inc SER.A:SERINA THERAPEUTICS ANNOUNCES NYSE AMERICAN ACCEPTANC","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA8JYXP2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624823066","title":"NYSE American accepts Serina plan to regain listing compliance by July 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2624823066","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624823066?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:13","pubTimestamp":1775160821,"startTime":"0","endTime":"0","summary":"NYSE American accepted Serina Therapeutics’ plan to regain compliance with continued listing standards.Cure period runs through July 9, 2027, with shares remaining listed during that time subject to other standards.Company received a noncompliance notice on Jan. 9, 2026 tied to stockholders’ equity of $1.6 million.NYSE American will monitor progress quarterly, with suspension and delisting procedures possible if targets are not met by deadline.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL4thyMN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4112","LU2210150020.SGD","NDAQ","SG9999014005.SGD","IE00BN0W2W23.USD","BK4139","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014039.USD","BK4585","SG9999014021.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BN0W2V16.EUR","SER","LU0314104364.USD","BK4588","IE00BGHQF748.EUR","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624682341","title":"Serina Therapeutics Announces Nyse American Acceptance of Continued Listing Compliance Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2624682341","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624682341?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:13","pubTimestamp":1775160780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA8JYXP2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SER","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622016822","title":"Analysts’ Top Healthcare Picks: Serina Therapeutics (SER), Pharma Mar SA (PHMMF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622016822","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622016822?lang=en_us&edition=fundamental","pubTime":"2026-03-27 21:40","pubTimestamp":1774618806,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Serina Therapeutics (SER) and Pharma Mar SA (PHMMF) ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-serina-therapeutics-ser-pharma-mar-sa-phmmf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-serina-therapeutics-ser-pharma-mar-sa-phmmf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHMMF","BK4585","XBI","LU0128526141.USD","BK4581","LABU","XLV","LU0029874061.USD","HCSG","SER","BK4139","BK4137","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622047250","title":"Serina Therapeutics, Inc FY Revenue USD 130 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2622047250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622047250?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:20","pubTimestamp":1774470000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nPLXAE51EF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SER","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622045250","title":"Serina Therapeutics FY2025 net loss widens 71.46% to $(19.2) million; revenue rises more than doubled to $130,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2622045250","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622045250?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:04","pubTimestamp":1774469078,"startTime":"0","endTime":"0","summary":"Serina published its annual report on Form 10-K, reporting a net loss of USD 19.2 million and grant revenues of USD 130,000.Research and development expense rose 75.9% to USD 13.2 million, driven mainly by higher clinical activities, increased headcount-related compensation, and higher consultant and outsourced research spend.General and administrative expense increased 14.3% to USD 11.0 million, primarily due to higher stock-based compensation, public company infrastructure consulting, and investor outreach, partly offset by lower legal and certain professional fees.Cash and cash equivalents were USD 3.1 million, and net cash used in operating activities was USD 18.0 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Thera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL8FzlHq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622114940","title":"Serina Therapeutics Chief Scientific Officer Moreadith Randall disposes of USD 18,568 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2622114940","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622114940?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:25","pubTimestamp":1774394703,"startTime":"0","endTime":"0","summary":"Moreadith Randall, Chief Scientific Officer at Serina Therapeutics, exercised stock options and acquired 6,500 shares at an exercise price of USD 0.06 per share.Randall sold 6,500 shares at a weighted average price of USD 2.86 per share.After the transactions, Randall reported 0 shares of common stock directly owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL8JyXj7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Serina Therapeutics Chief Scientific Officer Moreadith Randall disposes of USD 18,568 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621673063","title":"Serina Therapeutics CEO to present at the 38th Annual Roth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2621673063","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621673063?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:00","pubTimestamp":1774346434,"startTime":"0","endTime":"0","summary":"Serina will participate in a fireside chat at the 38th Annual Roth Conference in Dana Point, California on March 24, 2026.Chief Executive Officer Steve Ledger is scheduled to present at 11:30 a.m. PST.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL1HpVdT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014021.USD","BK4585","LU2095319765.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","SG9999014005.SGD","SER","IE00BN0W2T93.GBP","NDAQ","SG9999014039.USD","BK4139","LU0314104364.USD","IE00BKPKM429.USD","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621108412","title":"BRIEF-Serina Therapeutics Inc - Appoints Greg Bailey As Co-Chairman Of Board - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621108412","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621108412?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:29","pubTimestamp":1774297785,"startTime":"0","endTime":"0","summary":"BRIEF-Serina Therapeutics Inc - Appoints Greg Bailey As Co-Chairman Of Board - SEC FilingMarch 23  - Serina Therapeutics Inc SER.A:SERINA THERAPEUTICS INC - APPOINTS GREG BAILEY AS CO-CHAIRMAN OF BOARD - SEC FILINGSource text: [ID:n0001708599-26-000010]Further company coverage: SER.A ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0VP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621690084","title":"Serina Therapeutics Inc - Appoints Greg Bailey as Co-Chairman of Board - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621690084","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621690084?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:25","pubTimestamp":1774297514,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0VP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SER","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621081272","title":"Serina Therapeutics raises up to USD 30 million to advance SER-252 registrational trial in advanced Parkinson’s disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2621081272","media":"Reuters","labels":["executive","shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621081272?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:09","pubTimestamp":1774296547,"startTime":"0","endTime":"0","summary":"Serina reported progress on SER-252 for advanced Parkinson’s disease, with proceeds from a USD 15.0 million private placement intended to support its registrational study under a 505 pathway.Warrant coverage tied to the placement could add up to USD 33.3 million in future proceeds, subject to exercise, increasing resources available for the program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLcbj9c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621557277","title":"Serina Therapeutics CSO Randall Moreadith disposed of USD 97,500 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2621557277","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621557277?lang=en_us&edition=fundamental","pubTime":"2026-03-21 02:21","pubTimestamp":1774030881,"startTime":"0","endTime":"0","summary":"Randall Moreadith, Chief Scientific Officer at Serina Therapeutics, reported exercising stock options for 39,000 common shares at USD 0.06 per share.She also reported selling 39,000 common shares at USD 2.5 per share.Following the transactions, she reported 0 common shares owned directly.She reported beneficial ownership of 274,186 stock options after the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL5sfMHB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Serina Therapeutics CSO Randall Moreadith disposed of USD 97,500 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620782897","title":"Stock Market Today: S&P 500, Dow Futures Down Ahead Of 'Triple Witching' As Iran Warns Of 'Zero Restraint'—FedEx, Super Micro Computer In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2620782897","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620782897?lang=en_us&edition=fundamental","pubTime":"2026-03-20 17:58","pubTimestamp":1774000692,"startTime":"0","endTime":"0","summary":"U.S. stock futures declined on Friday following Thursday’s declines. Futures of the major benchmark indices were lower.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"0f1c115038e2d548615a3cf9bc49c55d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/03/51373609/stock-market-today-sp-500-dow-futures-down-ahead-of-triple-witching-as-iran-warns-of-zero-restraint-fedex-super-micro-computer-in-focus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPIX","LU0128525689.USD","LU1571399168.USD","SMCZ","BK4533","RSP","SPXL","BK4131","BK4111","JEPI","SMCL","BK4559","FDX","LU1267930227.SGD","SH","SPXU","HIBL","PLU","LU0251131958.USD","LU0310800965.SGD","IVV","SPMO","UPRO","XYLD","TECL","SMCC","SPYI","BK4543","BK4504","SDS","SMCI","BK4588","SPXS","BMAY","VTI","BK4170","SCHL","LU0052756011.USD","OEX","SPYV","LU0053671581.USD","LU1861220033.SGD","SER","SMYY","BK4139","SMCY","BK4550","SMCX","BK4593","LU0048573561.USD","BK4123","SPDN","BK4585","BK4581","BK4534","LU0251142724.SGD","SPYG","LU0742534661.SGD","IVOO","ESmain","XDTE","SPLV","IVW","LU1861215975.USD","BK4561","MESmain","OEF","SSO","VTV",".SPX","SPYM"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620706220","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2620706220","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620706220?lang=en_us&edition=fundamental","pubTime":"2026-03-20 01:31","pubTimestamp":1773941506,"startTime":"0","endTime":"0","summary":"Serina Therapeutics  shares rose in midday trading on Thursday after the company said late Wednesday it has entered agreements to offer common shares and pre-funded warrants at $2.25 apiece for gross proceeds of $15 million.Shares jumped roughly 115% in midday trading as volume climbed to more than 125.9 million from a daily average of about 1.5 million.Envela  shares were up nearly 44% after the company reported higher Q4 results late Wednesday.Intraday trading volume rose to over 1.3 million shares from a daily average of about 81,000.Duluth Holdings  stock was up about 43% after the company swung to adjusted earnings of $0.23 per share in fiscal Q4 from a loss of $0.10 per share in the same quarter a year ago.Intraday trading volume stood at nearly 10.9 million shares versus a daily average of roughly 63,000.Price: 2.73, Change: +1.45, Percent Change: +112.89","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4200","ELA","BK4122","BK7095","SER.AU","BK4139","SER","DLTH","BK4094"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.serinatx.com","stockEarnings":[{"period":"1week","weight":-0.1475},{"period":"1month","weight":-0.2041},{"period":"3month","weight":-0.0824},{"period":"6month","weight":-0.6186},{"period":"1year","weight":-0.7329},{"period":"ytd","weight":-0.1845}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0819},{"period":"3month","weight":0.0896},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.2649},{"period":"ytd","weight":0.0886}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.123641},{"month":2,"riseRate":0.375,"avgChangeRate":-0.090531},{"month":3,"riseRate":0.625,"avgChangeRate":0.019814},{"month":4,"riseRate":0.375,"avgChangeRate":-0.064978},{"month":5,"riseRate":0.25,"avgChangeRate":-0.069419},{"month":6,"riseRate":0.714286,"avgChangeRate":0.141504},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.044804},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.113434},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.1034},{"month":10,"riseRate":0.428571,"avgChangeRate":0.074812},{"month":11,"riseRate":0.142857,"avgChangeRate":-0.13511},{"month":12,"riseRate":0.375,"avgChangeRate":-0.03882}],"exchange":"AMEX","name":"Serina Therapeutics, Inc.","nameEN":"Serina Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Serina Therapeutics, Inc.(SER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Serina Therapeutics, Inc.(SER) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Serina Therapeutics, Inc.,SER,Serina Therapeutics, Inc.股票,Serina Therapeutics, Inc.股票老虎,Serina Therapeutics, Inc.股票老虎国际,Serina Therapeutics, Inc.行情,Serina Therapeutics, Inc.股票行情,Serina Therapeutics, Inc.股价,Serina Therapeutics, Inc.股市,Serina Therapeutics, Inc.股票价格,Serina Therapeutics, Inc.股票交易,Serina Therapeutics, Inc.股票购买,Serina Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Serina Therapeutics, Inc.(SER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Serina Therapeutics, Inc.(SER) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction